Teva Releases Innovation and Social Responsibility Highlights
Leading Global Pharmaceutical Company Recaps Latest Milestones, from
Bolstering Digital Healthcare Start-Ups to Creating Tailored Treatments
JERUSALEM–(BUSINESS WIRE)–Teva
Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) released its Corporate
Social Responsibility Highlights today. In one year, Teva—the
world’s largest generic medicines maker and recognized leader in
specialty pharmaceuticals—launched more than 315 new generic medicines
to more than 200 million patients, in over 60 countries. Additionally,
Teva is on target to launch over 1000 new generic medicines in 2016 and
nearly 1500 new generic medicines in 2017 as well as 27 new specialty
products by 2019.
“We remain committed to ensuring that our medicines are available and
adapted to serve global and changing healthcare needs,” said Teva
President and CEO Erez
Vigodman. “The highlights released today demonstrate our evolution
over the last few years as we make healthcare accessible for billions of
people around the world and seek to reduce the burden on national
economies and investing in development to bring new therapeutic options
to patients.”
Teva’s work in decreasing generic prescription drug prices in the U.S.,
saving billions for the UK National Health Service, lowering greenhouse
gas emissions and other recent insights into the company’s social
responsibility and innovation efforts can be found in “Innovating
for Better Health: Teva Global Corporate Social Responsibility Highlights.”
Highlights include:
-
Creating the next generation of health startups. In January
2015, Teva, in collaboration with Phillips Healthcare, launched Sanara
Ventures. It is the first partnership of its kind in
Israel. The venture capital incubator committed to investing
approximately $26 million to support 40-50 early-stage digital
healthcare and medical device companies in the next eight years.
To date, out of 400 applications, four companies have received
funding, with two receiving full licensure in the digital health and
respiratory space. -
Enhancing patient treatment methods. Teva scientists are
playing a unique role in developing innovative therapies by
taking already known molecules and repurposing and transforming them
for better efficacy, safety and improved patient compliance. Current
new therapies are in advanced stages of development and include a
long-lasting, ready-to-use treatment for schizophrenia
patients. -
Personalized
medicine. Teva’s pharmacogenomics research in Israel is
working to identify specific genetic modifications among similar
communities. The potential exists to develop targeted treatments that
can prevent serious diseases in populations with similar genetic
markers. -
Supporting women in leadership positions around the globe. At
Teva, 49 percent of total management at all levels, and 35
percent of executives and senior management are women. Research
from 2015 on business diversity shows that around the world just
22 percent of senior roles are held by women, compared to 19 percent
in 2004.
These milestones align with the announcement of Teva’s Target Zero
vision to achieve zero incidents, zero injuries and zero releases into
the environment. As part of this vision, Teva pledged to reduce energy
consumption by 20 percent and reduce greenhouse gas emissions 15 percent
by 2020. Between 2012 and 2014, Teva cut greenhouse gas emissions by six
percent and reduced water usage by 17 percent in 2014 alone.
Each year, since 2011, Teva has responded to the climate change
information survey by the Carbon
Disclosure Project, most recently scoring a 96B out of a highest
possible score of 100A.
“These highlights demonstrate Teva’s continued commitment to offer real
value to patients and healthcare systems around the globe,” said Iris
Beck-Codner, Group Executive Vice President, Corporate Marketing
Excellence and Communications. “The report also highlights our sustained
efforts to preserve the environment, as well as our steadfast commitment
to ensure that Teva employees achieve their fullest potential in a
healthy work environment. As a whole, it reflects the progress we’ve
made, our vision for the future and our belief that the global
healthcare industry must play an increasingly integral role in creating
accessible, innovative and sustainable solutions for people everywhere.”
To learn more about Teva’s Corporate Social Responsibility efforts,
please visit: http://www.tevapharm.com/corporate_responsibility/.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading
global pharmaceutical company that delivers high-quality,
patient-centric healthcare solutions to millions of patients every day.
Headquartered in Israel, Teva is the world’s largest generic medicines
producer, leveraging its portfolio of more than 1,000 molecules to
produce a wide range of generic products in nearly every therapeutic
area. In specialty medicines, Teva has a world-leading position in
innovative treatments for disorders of the central nervous system,
including pain, as well as a strong portfolio of respiratory products.
Teva integrates its generics and specialty capabilities in its global
research and development division to create new ways of addressing unmet
patient needs by combining drug development capabilities with devices,
services and technologies. Teva’s net revenues in 2014 amounted to $20.3
billion. For more information, visit www.tevapharm.com.
Teva’s Safe Harbor Statement under the U. S. Private Securities
Litigation Reform Act of 1995:
This release contains forward-looking statements, which are based on
management’s current beliefs and expectations and involve a number of
known and unknown risks and uncertainties that could cause our future
results, performance or achievements to differ significantly from the
results, performance or achievements expressed or implied by such
forward-looking statements. Important factors that could cause or
contribute to such differences include risks relating to: our ability to
develop and commercialize additional pharmaceutical products;
competition for our innovative products, especially Copaxone®
(including competition from orally-administered alternatives, as well as
from potential purported generic equivalents) and our ability to
migrate users to our 40 mg/mL version; the possibility of material
fines, penalties and other sanctions and other adverse consequences
arising out of our ongoing FCPA investigations and related matters; our
ability to achieve expected results from the research and development
efforts invested in our pipeline of specialty and other products; our
ability to reduce operating expenses to the extent and during the
timeframe intended by our cost reduction program; our ability to
identify and successfully bid for suitable acquisition targets or
licensing opportunities, or to consummate and integrate acquisitions;
the extent to which any manufacturing or quality control problems damage
our reputation for quality production and require costly remediation;
increased government scrutiny in both the U.S. and Europe of our patent
settlement agreements; our exposure to currency fluctuations and
restrictions as well as credit risks; the effectiveness of our patents,
confidentiality agreements and other measures to protect the
intellectual property rights of our specialty medicines; the effects of
reforms in healthcare regulation and pharmaceutical pricing,
reimbursement and coverage; governmental investigations into sales and
marketing practices, particularly for our specialty pharmaceutical
products; adverse effects of political or economic instability, major
hostilities or acts of terrorism on our significant worldwide
operations; interruptions in our supply chain or problems with internal
or third-party information technology systems that adversely affect our
complex manufacturing processes; significant disruptions of our
information technology systems or breaches of our data security;
competition for our generic products, both from other pharmaceutical
companies and as a result of increased governmental pricing pressures;
competition for our specialty pharmaceutical businesses from companies
with greater resources and capabilities; the impact of continuing
consolidation of our distributors and customers; decreased opportunities
to obtain U.S. market exclusivity for significant new generic products;
potential liability in the U.S., Europe and other markets for sales of
generic products prior to a final resolution of outstanding patent
litigation; our potential exposure to product liability claims that are
not covered by insurance; any failure to recruit or retain key
personnel, or to attract additional executive and managerial talent; any
failures to comply with complex Medicare and Medicaid reporting and
payment obligations; significant impairment charges relating to
intangible assets, goodwill and property, plant and equipment; the
effects of increased leverage and our resulting reliance on access to
the capital markets; potentially significant increases in tax
liabilities; the effect on our overall effective tax rate of the
termination or expiration of governmental programs or tax benefits, or
of a change in our business; variations in patent laws that may
adversely affect our ability to manufacture our products in the most
efficient manner; environmental risks; and other factors that are
discussed in our Annual Report on Form 20-F for the year ended December
31, 2014 and in our other filings with the U.S. Securities and Exchange
Commission. Forward-looking statements speak only as of the date on
which they are made and we assume no obligation to update or revise any
forward-looking statement, whether as a result of new information,
future events or otherwise.
Contacts
Teva Pharmaceutical Industries Ltd.
IR Contacts:
United
States
Kevin C. Mannix, (215) 591-8912
Ran Meir, (215)
591-3033
or
Israel
Tomer Amitai, 972 (3) 926-7656
or
PR
Contacts:
Israel
Iris Beck Codner, 972 (3) 926-7687
or
United
States
Denise Bradley, (215) 591-8974
